Nombre de documents


Patrizia Giannoni

Article dans une revue4 documents

  • Farron Mcintee, Patrizia Giannoni, Steven Blais, George Sommer, Thomas Neubert, et al.. In vivo Differential Brain Clearance and Catabolism of Monomeric and Oligomeric Alzheimer's Aβ protein. Frontiers in Aging Neuroscience, Frontiers, 2016, 8, 〈10.3389/fnagi.2016.00223〉. 〈hal-01705732〉
  • Patrizia Giannoni, Margarita Arango-Lievano, Ines Das Neves, Marie-Claude Ă Rousset, Kévin Baranger, et al.. Cerebrovascular pathology during the progression of experimental ă Alzheimer's disease. Neurobiology of Disease, Elsevier, 2016, 88, pp.107-117. 〈10.1016/j.nbd.2016.01.001〉. 〈hal-01477817〉
  • Cédric Lecoutey, Damien Hedou, Thomas Freret, Patrizia Giannoni, Florence Gaven, et al.. Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor withpotential interest for Alzheimer's disease treatment.. Proceedin, 2014, 111 (36), pp.3825-3830. 〈hal-01064797〉
  • Patrizia Giannoni, Florence Gaven, Dimitri De Bundel, Kevin Baranger, Evelyne Marchetti-Gauthier, et al.. Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer’s disease. Frontiers in Aging Neuroscience, Frontiers, 2013, 5, 〈10.3389/fnagi.2013.00096〉. 〈hal-01703910〉